Nexalin Technology (NXL) Cash from Investing Activities (2023 - 2026)
Nexalin Technology's (NXL) quarterly Cash from Investing Activities came in at $1.5 million in Q1 2026, up 2.44% year-on-year from $1.5 million in Q1 2025, and up 119.05% quarter-over-quarter from $689180.0 in Q4 2025.
Nexalin Technology (NXL) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Nexalin Technology's Cash from Investing Activities history runs 4 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 2.44% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was -$96070.0, a 157.56% decrease from a year earlier, with the FY2025 full-year figure at -$131991.0, up 77.15% from the prior year.
- Cash from Investing Activities climbed to $1.5 million in Q1 2026 per NXL's latest filing, from $689180.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $1.6 million in Q4 2024 and bottomed at -$4.5 million in Q3 2024.
- The 4-year median for Cash from Investing Activities is $1.2 million (2023), against an average of $404078.5.
- Across the five-year window, Cash from Investing Activities tumbled 639.66% in 2024 and jumped 136.25% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at $1.2 million in 2023, then soared by 33.09% to $1.6 million in 2024, then tumbled by 57.66% to $689180.0 in 2025, then jumped by 119.05% to $1.5 million in 2026.
- Per Business Quant, the three latest NXL Cash from Investing Activities figures stand at $1.5 million (Q1 2026), $689180.0 (Q4 2025), and $1.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Nexalin Technology | 9.07 Mn | 6.36 Mn | 13,133.00 | 1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 689,180.00 |
| Dec 31, 2025 | 689,180.00 |
| Sep 30, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | -3.92 Mn |
| Jun 30, 2025 | -3.92 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 729,314.00 |
| Mar 31, 2024 | 729,314.00 |
| Dec 31, 2023 | 1.22 Mn |
| Dec 31, 2023 | 1.22 Mn |